Dublin, Ireland-based Shire plans to consolidate more than 3,000 staffers spread out at over half-a-dozen locations across Massachusetts to two campuses in Cambridge and Lexington.
FDA approves Baxalta’s treatment for common bleeding disorder
Approvals, Biotech, Bleeding, Bleeding Disorders, Blood Clots, Blood Clots, FDA, FDA/Regulatory, gegetic, Genetic Engineering, Genetics, Health, Hemophilia, Hemophilia, Immune Systems, Joints, Muscles, Oncology, Orphan Diseases, Orphan Drugs, Proteins, Rare Diseases, Shares, Shares, Willebrand DiseaseThe U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand […]
